期刊
FRONTIERS IN PEDIATRICS
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fped.2022.975819
关键词
acute myeloid leukemia; pediatric; epigenetics; DNA methylation; histone modification; non-coding RNAs; therapy
类别
资金
- National Natural Science Foundation of China
- [31701207]
This review discusses the genetic alterations and epigenetic dysregulations of hematopoietic progenitor cells in acute myeloid leukemia (AML), emphasizing the role of epigenetic abnormalities in leukemogenesis. The current progress in epigenetic targeted therapy and its potential value in precision and combinational therapy for pediatric AML are also described.
Acute myeloid leukemia (AML) is a hematological malignancy resulting from the genetic alterations and epigenetic dysregulations of the hematopoietic progenitor cells. One-third of children with AML remain at risk of relapse even though outcomes have improved in recent decades. Epigenetic dysregulations have been identified to play a significant role during myeloid leukemogenesis. In contrast to genetic changes, epigenetic modifications are typically reversible, opening the door to the development of epigenetic targeted therapy. In this review, we provide an overview of the landscape of epigenetic alterations and describe the current progress that has been made in epigenetic targeted therapy, and pay close attention to the potential value of epigenetic abnormalities in the precision and combinational therapy of pediatric AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据